Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Trial details
- Registry ID
- NCT05303064
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as ALKS 3831; ALKS 3831, LYBALVI
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-12Estimated |
| Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229 | Alkermes, Inc. | Phase 3 | Enrolling by invitation | 2027-09Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |